^
    Back
    Association details:
    Biomarker:MYC amplification
    Cancer:Melanoma
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ESMO Open
    Title:

    Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment

    Published date:
    12/15/2020
    Excerpt:
    Next-generation sequencing (NGS) was performed using tumor specimens collected from 178 Asian patients with metastatic melanoma receiving CPIs….MYC and RPS6KB1 amplifications were associated with responsiveness to CPIs (P < 0.05).
    DOI:
    10.1016/j.esmoop.2020.100002
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    Molecular features for selecting Asian metastatic melanoma patients who benefit from check-point inhibitors.

    Published date:
    05/13/2020
    Excerpt:
    NRAS and TP53 mutation and NF2 deletion were significantly related to patients without the response to CPIs (p < 0.05). Meanwhile, MYC and RPS6KB1 amplification were found with those with the response (p < 0.05). The median progression free survival (PFS) to ICIS was 5.9 months (95% CI 3.8 - 8.05 months).
    DOI:
    10.1200/JCO.2020.38.15_suppl.e22011